{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T07:00:45Z","timestamp":1793948445714,"version":"4.8.0"},"reference-count":55,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Arch Dis Child"],"published-print":{"date-parts":[[2016,4]]},"abstract":"<jats:p>Nephrotic syndrome is one of the most common paediatric glomerular diseases, with an incidence of around two per 100\u2005000\u00a0children per year. Corticosteroids are the mainstay of treatment, with 85%\u201390% of children going into remission with an 8-week course of treatment. Unfortunately, nephrotic syndrome follows a relapsing and remitting course in the majority, with 90% relapsing at least once. About half will progress to frequently relapsing nephrotic syndrome (FRNS) or steroid-dependent nephrotic syndrome (SDNS). Different initial steroid regimens have been evaluated since the first trials in Europe and America in the 1960s. Most trials have been designed to evaluate the optimal duration of the initial therapy, rather than different cumulative doses of corticosteroid, or the management of relapses. Until recently, these data suggested that an initial treatment duration of up to 6\u2005months reduced the number of children developing a relapse, without evidence of increased steroid toxicity. Recently, three large, well-designed randomised control trials were published, which demonstrated no significant reduction in risk of relapse or of developing FRNS by extended treatment compared with 2 or 3\u2005months. While there are few trial data to guide the treatment of individual relapses in steroid-sensitive nephrotic syndrome (SSNS), there is some evidence that a short course of corticosteroid therapy during upper respiratory tract infection may prevent relapse. In patients with FRNS or SDNS who continue to relapse despite low-dose alternate-day steroids a number of non-corticosteroid, steroid-sparing immunosuppressive agents (cyclophosphamide, ciclosporin, tacrolimus, mycophenolate mofetil, levamisole, rituximab) have been shown to reduce the risk of relapse and of FRNS. However, there are limited head-to-head data to inform which agent should be preferred. In this article, we review recent data from randomised trials to update paediatricians on the current evidence supporting interventions in SSNS.<\/jats:p>","DOI":"10.1136\/archdischild-2015-308924","type":"journal-article","created":{"date-parts":[[2015,8,20]],"date-time":"2015-08-20T02:19:47Z","timestamp":1440037187000},"page":"404-408","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":42,"title":["Steroid-sensitive nephrotic syndrome: an evidence-based update of immunosuppressive treatment in children"],"prefix":"10.1136","volume":"101","clinical-trial-number":[{"clinical-trial-number":"isrctn16645249","registry":"10.18810\/isrctn"},{"clinical-trial-number":"isrctn10900733","registry":"10.18810\/isrctn"}],"author":[{"given":"Nicholas","family":"Larkins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siah","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Craig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Hodson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2015,8,19]]},"reference":[{"key":"key-10.1136\/archdischild-2015-308924-1","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s00467-011-1851-8","article-title":"Nephrotic syndrome in the Netherlands: a population-based cohort study and a review of the literature","volume":"26","author":"El Bakkali","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"key-10.1136\/archdischild-2015-308924-2","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1007\/s004670100021","article-title":"Time trends and ethnic patterns of childhood nephrotic syndrome in Yorkshire, UK","volume":"16","author":"McKinney","year":"2001","journal-title":"Pediatr Nephrol"},{"key":"key-10.1136\/archdischild-2015-308924-3","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1440-1754.2007.01077.x","article-title":"Idiopathic nephrotic syndrome in New Zealand children, demographic, clinical features, initial management and outcome after twelve-month follow-up: results of a three-year national surveillance study","volume":"43","author":"Wong","year":"2007","journal-title":"J Paediatr Child Health"},{"key":"key-10.1136\/archdischild-2015-308924-4","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1001\/archpedi.1968.02100020627009","article-title":"The nephrotic syndrome. Its incidence and implications for the community","volume":"116","author":"Schlesinger","year":"1968","journal-title":"Am J Dis Child"},{"key":"key-10.1136\/archdischild-2015-308924-5","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2188\/jea.JE20120033","article-title":"Epidemiology and predictors of end-stage renal disease in Taiwanese children with idiopathic nephrotic syndrome","volume":"22","author":"Chang","year":"2012","journal-title":"J Epidemiol"},{"key":"key-10.1136\/archdischild-2015-308924-6","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0031-3955(16)32565-2","article-title":"The nephrotic syndrome","volume":"18","author":"Arneil","year":"1971","journal-title":"Pediatr Clin North Am"},{"issue":"(4)","key":"key-10.1136\/archdischild-2015-308924-7","first-page":"CD001533","article-title":"Corticosteroid therapy for nephrotic syndrome in children","author":"Hodson","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"key-10.1136\/archdischild-2015-308924-8","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S0140-6736(85)91387-X","article-title":"Long-term outcome for children with minimal-change nephrotic syndrome","volume":"1","author":"Trompeter","year":"1985","journal-title":"Lancet"},{"key":"key-10.1136\/archdischild-2015-308924-9","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(03)14184-0","article-title":"Nephrotic syndrome in childhood","volume":"362","author":"Eddy","year":"2003","journal-title":"Lancet"},{"key":"key-10.1136\/archdischild-2015-308924-10","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/MOP.0b013e3282f4307a","article-title":"Evaluation and management of steroid-sensitive nephrotic syndrome","volume":"20","author":"Hodson","year":"2008","journal-title":"Curr Opin Pediatr"},{"key":"key-10.1136\/archdischild-2015-308924-11","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0140-6736(70)91093-7","article-title":"Controlled trial of azathioprine in children with nephrotic syndrome","volume":"295","author":"Abramowicz","year":"1970","journal-title":"Lancet"},{"key":"key-10.1136\/archdischild-2015-308924-12","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/B978-0-323-04883-5.50018-0","article-title":"Nephrotic syndrome","volume-title":"Comprehensive pediatric nephrology","author":"Gbadegesin","year":"2008"},{"key":"key-10.1136\/archdischild-2015-308924-13","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1056\/NEJM198202253060803","article-title":"Effect of cytotoxic drugs in frequently relapsing nephrotic syndrome with and without steroid dependence. A report of the \u201cArbetsgemeinschaft f\u00fcr P\u00e4diatrische Nephrologie\u201d","volume":"306","year":"1982","journal-title":"N Engl J Med"},{"key":"key-10.1136\/archdischild-2015-308924-14","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00467-012-2310-x","article-title":"Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO","volume":"28","author":"Lombel","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"key-10.1136\/archdischild-2015-308924-15","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/ki.2011.195","article-title":"Clinical trial of focal segmental glomerulosclerosis in children and young adults","volume":"80","author":"Gipson","year":"2011","journal-title":"Kidney Int"},{"key":"key-10.1136\/archdischild-2015-308924-16","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0022-3476(81)80760-3","article-title":"The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children","volume":"98","author":"ISKDC","year":"1981","journal-title":"J Pediatr"},{"key":"key-10.1136\/archdischild-2015-308924-17","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1681\/ASN.V85769","article-title":"Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children","volume":"8","author":"Tarshish","year":"1997","journal-title":"J Am Soc Nephrol"},{"key":"key-10.1136\/archdischild-2015-308924-18","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s00467-013-2736-9","article-title":"Predictors of remission and relapse in idiopathic nephrotic syndrome: a prospective cohort study","volume":"29","author":"Sureshkumar","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"key-10.1136\/archdischild-2015-308924-19","first-page":"401","article-title":"Alternate-day versus intermittent prednisone in frequently relapsing nephrotic syndrome. A report of \u201cArbetsgemeinschaft f\u00fcr P\u00e4diatrische Nephrologie\u201d","volume":"1","year":"1979","journal-title":"Lancet"},{"key":"key-10.1136\/archdischild-2015-308924-20","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1136\/adc.83.1.45","article-title":"Corticosteroid therapy in nephrotic syndrome: a meta-analysis of randomised controlled trials","volume":"83","author":"Hodson","year":"2000","journal-title":"Arch Dis Child"},{"key":"key-10.1136\/archdischild-2015-308924-21","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1681\/ASN.2012070646","article-title":"Extending prednisolone treatment does not reduce relapses in childhood nephrotic syndrome","volume":"24","author":"Teeninga","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"key-10.1136\/archdischild-2015-308924-22","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ki.2014.354","article-title":"New lessons from randomized trials in steroid-sensitive nephrotic syndrome: clear evidence against long steroid therapy","volume":"87","author":"Hoyer","year":"2015","journal-title":"Kidney Int"},{"key":"key-10.1136\/archdischild-2015-308924-23","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/ki.2014.240","article-title":"Extending initial prednisolone treatment in a randomized control trial from 3 to 6 months did not significantly influence the course of illness in children with steroid-sensitive nephrotic syndrome","volume":"87","author":"Sinha","year":"2015","journal-title":"Kidney Int"},{"key":"key-10.1136\/archdischild-2015-308924-24","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/ki.2014.260","article-title":"A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment","volume":"87","author":"Yoshikawa","year":"2015","journal-title":"Kidney Int"},{"key":"key-10.1136\/archdischild-2015-308924-25","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"key":"key-10.1136\/archdischild-2015-308924-26","first-page":"CD001533","article-title":"Corticosteroid therapy for nephrotic syndrome in children","volume":"3","author":"Hahn","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"key-10.1136\/archdischild-2015-308924-27","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s00467-015-3106-6","article-title":"Corticosteroids for the initial episode of steroid-sensitive nephrotic syndrome","volume":"30","author":"Hodson","year":"2015","journal-title":"Pediatr Nephrol"},{"key":"key-10.1136\/archdischild-2015-308924-28","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1159\/000045684","article-title":"Increased maintenance corticosteroids during upper respiratory infection decrease the risk of relapse in nephrotic syndrome","volume":"85","author":"Mattoo","year":"2000","journal-title":"Nephron"},{"issue":"(Suppl 1)","key":"key-10.1136\/archdischild-2015-308924-29","doi-asserted-by":"crossref","first-page":"A155","DOI":"10.1136\/archdischild-2014-306237.358","article-title":"G376(P) Short course of daily prednisolone during upper respiratory tract infection reduces the risk of relapse in childhood nephrotic syndrome","volume":"99","author":"Abeyagunawardena","year":"2014","journal-title":"Arch Dis Child"},{"key":"key-10.1136\/archdischild-2015-308924-30","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1136\/adc.2007.116079","article-title":"Increasing the dose of prednisolone during viral infections reduces the risk of relapse in nephrotic syndrome: a randomised controlled trial","volume":"93","author":"Abeyagunawardena","year":"2008","journal-title":"Arch Dis Child"},{"key":"key-10.1136\/archdischild-2015-308924-31","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2215\/CJN.01850310","article-title":"Daily corticosteroids reduce infection-associated relapses in frequently relapsing nephrotic syndrome: a randomized controlled trial","volume":"6","author":"Gulati","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"key-10.1136\/archdischild-2015-308924-32","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/1745-6215-15-147","article-title":"Short course daily prednisolone therapy during an upper respiratory tract infection in children with relapsing steroid-sensitive nephrotic syndrome (PREDNOS 2): protocol for a randomised controlled trial","volume":"15","author":"Webb","year":"2014","journal-title":"Trials"},{"key":"key-10.1136\/archdischild-2015-308924-33","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1053\/j.ajkd.2007.02.270","article-title":"Long-term outcome after cyclophosphamide treatment in children with steroid-dependent and frequently relapsing minimal change nephrotic syndrome","volume":"49","author":"Kyrieleis","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"key-10.1136\/archdischild-2015-308924-34","first-page":"CD002290","article-title":"Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children","volume":"10","author":"Pravitsitthikul","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"key-10.1136\/archdischild-2015-308924-35","first-page":"1326","article-title":"Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: a multicentre randomized controlled trial","volume":"8","author":"Ponticelli","year":"1993","journal-title":"Nephrol Dial Transplant"},{"key":"key-10.1136\/archdischild-2015-308924-36","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1007\/s00467-012-2228-3","article-title":"Treatment of tacrolimus or cyclosporine A in children with idiopathic nephrotic syndrome","volume":"27","author":"Wang","year":"2012","journal-title":"Pediatr Nephrol"},{"key":"key-10.1136\/archdischild-2015-308924-37","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1053\/j.ajkd.2008.11.033","article-title":"Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: a randomized controlled trial","volume":"53","author":"Choudhry","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"key-10.1136\/archdischild-2015-308924-38","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1681\/ASN.2012121200","article-title":"Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome","volume":"24","author":"Gellermann","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"key-10.1136\/archdischild-2015-308924-39","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1007\/s00467-008-0899-6","article-title":"Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome","volume":"23","author":"Dorresteijn","year":"2008","journal-title":"Pediatr Nephrol"},{"key":"key-10.1136\/archdischild-2015-308924-40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ajmg.a.32117","article-title":"In utero exposure to mycophenolate mofetil: a characteristic phenotype?","volume":"146A","author":"Perez-Aytes","year":"2008","journal-title":"Am J Med Genet A"},{"key":"key-10.1136\/archdischild-2015-308924-41","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/S0140-6736(14)60654-1","article-title":"Rituximab for childhood-onset nephrotic syndrome","volume":"384","author":"Hodson","year":"2014","journal-title":"Lancet"},{"key":"key-10.1136\/archdischild-2015-308924-42","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1681\/ASN.2013030251","article-title":"Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome","volume":"25","author":"Ruggenenti","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"key-10.1136\/archdischild-2015-308924-43","doi-asserted-by":"crossref","DOI":"10.1681\/ASN.2014080799","article-title":"Rituximab in children with steroid-dependent nephrotic syndrome: a multicenter, open-label, noninferiority, randomized controlled trial","author":"Ravani","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"key-10.1136\/archdischild-2015-308924-44","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1093\/ndt\/gfr405","article-title":"Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood\u2014follow-up after CD19 recovery","volume":"27","author":"Sellier-Leclerc","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"key-10.1136\/archdischild-2015-308924-45","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/ndt\/gfu267","article-title":"Efficacy and safety of rituximab in children with difficult-to-treat nephrotic syndrome","volume":"30","author":"Sinha","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"key-10.1136\/archdischild-2015-308924-46","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s00467-012-2406-3","article-title":"Long-term outcome of children treated with rituximab for idiopathic nephrotic syndrome","volume":"28","author":"Tellier","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"key-10.1136\/archdischild-2015-308924-47","first-page":"1","article-title":"Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial","volume":"6736","author":"Iijima","year":"2014","journal-title":"Lancet"},{"key":"key-10.1136\/archdischild-2015-308924-48","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1007\/s00467-009-1195-9","article-title":"Fatal pulmonary fibrosis after rituximab administration","volume":"24","author":"Chaumais","year":"2009","journal-title":"Pediatr Nephrol"},{"key":"key-10.1136\/archdischild-2015-308924-49","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1007\/s00467-013-2457-0","article-title":"Difficulties in diagnosing severe Pneumocystis jiroveci pneumonia after rituximab therapy for steroid-dependent nephrotic syndrome","volume":"28","author":"Czarniak","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"key-10.1136\/archdischild-2015-308924-50","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1007\/s00467-013-2485-9","article-title":"Fulminant viral myocarditis after rituximab therapy in pediatric nephrotic syndrome","volume":"28","author":"Sellier-Leclerc","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"key-10.1136\/archdischild-2015-308924-51","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1001\/archneurol.2011.103","article-title":"Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis","volume":"68","author":"Clifford","year":"2011","journal-title":"Arch Neurol"},{"key":"key-10.1136\/archdischild-2015-308924-52","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/pds.3320","article-title":"Signals of progressive multifocal leukoencephalopathy for immunosuppressants: a disproportionality analysis of spontaneous reports within the US Adverse Event Reporting System (AERS)","volume":"21","author":"Schmedt","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"key-10.1136\/archdischild-2015-308924-53","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s00467-004-1615-9","article-title":"Levamisole in steroid-sensitive nephrotic syndrome of childhood: the lost paradise?","volume":"20","author":"Davin","year":"2005","journal-title":"Pediatr Nephrol"},{"key":"key-10.1136\/archdischild-2015-308924-54","article-title":"The levamisole study in steroid sensitive idiopathic nephrotic syndrome (SSINS): inclusion completed","author":"Mariken","year":"2012"},{"key":"key-10.1136\/archdischild-2015-308924-55","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1523-1755.2000.00168.x","article-title":"A multicenter trial of mizoribine compared with placebo in children with frequently relapsing nephrotic syndrome","volume":"58","author":"Yoshioka","year":"2000","journal-title":"Kidney Int"}],"container-title":["Archives of Disease in Childhood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/archdischild-2015-308924","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T17:46:44Z","timestamp":1653068804000},"score":1,"resource":{"primary":{"URL":"https:\/\/adc.bmj.com\/lookup\/doi\/10.1136\/archdischild-2015-308924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,19]]},"references-count":55,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2016,3,17]]},"published-print":{"date-parts":[[2016,4]]}},"alternative-id":["10.1136\/archdischild-2015-308924"],"URL":"https:\/\/doi.org\/10.1136\/archdischild-2015-308924","relation":{},"ISSN":["0003-9888","1468-2044"],"issn-type":[{"value":"0003-9888","type":"print"},{"value":"1468-2044","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,19]]}}}